Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS

Vyome Holdings, Inc. HIND

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$319,714
▲ 24.4% YoY
$-10.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The Company also has a Pre-Investigational New Drug application stage ophthalmic drops program, a potential orphan drug program, VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis. The Company also has commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (“MRT”) in India - a dandruff lotion and shampoo. The Company operates in two segments, biotechnology and pharmaceutical products. Our biotechnology segment comprises our operations around our VT-1953, VT-1908, and VB-1953 programs that are in development, and our pharmaceutical segment comprises our antifungal products. We were incorporated as a Delaware company in 2017.

Written from the business description in Vyome Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 18 March 2026. Every sentence was checked against that document before publication.

Growth

USD 319,714.00
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.3 · Net income -10.3
5.0M10.0M-25.0M-50.0M
20142017202020232025
Compound annual growth
−69.5%
−51.0%
−22.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −51.0% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -3269.4% · Net ·
-1000%-2000%-3000%
201420192025
ROE
FY2023 · ROE -220.6%
-100%-200%
201420192025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -17.0
-15M-30M
201420192025

Total assetsUSD 6.5M
CashUSD 5.0M
Current ratio1.99×

Not available: we don't have the total debt figure for this period.

The 12-year record

12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
HIND, 12-year financial record
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B◌−0.0−0.0−0.0−0.1−0.0−0.0◌◌◌◌◌
Income tax $B◌0.00.0−0.0−0.0−0.00.00.00.00.0−0.00.0
Net income $B−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌◌−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−4.86−6001.39−110.87−108.90−288.97−5.54−5.03−19.64−2.08−4.85−27.14−18.61
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————
ROE %——−220.6−192.6−214.7−112.1−127.2−155.0−69.9———
Shares out B0.010.000.000.000.020.000.010.020.020.020.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 58 reconciliationsAUDITED

Reconciled in 12 of the 12 fiscal years we could check. 16 checks were skipped: the balance sheet is not tagged before 2015. Seven checks were skipped: EPS is not tagged before 2014. Seven checks were skipped: revenue is not tagged before 2014.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2014

Share this section

Download image